Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 6/20 | 0.33 |
| ▸ | TDO2 | P48775 | 6/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.30 |
| ▸ | MERTK | Q12866 | 1/20 | 0.30 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.30 |
| ▸ | OGA | O60502 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19975363 | 0.85 | IDO1 (0.31) | IDO1TDO2 | |
| SCHEMBL19975213 | 0.85 | IDO1 (0.31) | IDO1TDO2 | |
| Hydrochloric Acid SCHEMBL19975373 | 0.84 | LOXL2 (0.31) | IDO1TDO2 | |
| SCHEMBL18975035 | 0.79 | FLT3 (0.33) | SLC5A2HRH3FLT3TYRO3MERTK | |
| SCHEMBL19975474 | 0.79 | LMNA (0.31) | — | |
| SCHEMBL19975224 | 0.79 | — | — | |
| SCHEMBL19984507 | 0.78 | — | — | |
| SCHEMBL19984737 | 0.77 | TRPV3 (0.34) | — | |
| SCHEMBL17282699 | 0.76 | WDR5 (0.34) | SLC5A2TDO2HRH3FLT3TYRO3 | |
| SCHEMBL16552392 | 0.74 | KMT2A (0.36) | TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220023311-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2022-01-27 | — | — | US | disclosed |
| US-10987360-B2 | Hepatitis B core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-10987360-B2 | Hepatitis B core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20190255067-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2019-08-22 | — | — | US | disclosed |
| US-20190255067-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2019-08-22 | — | — | US | disclosed |
| EP-3512845-A1 | HEPATITIS B CORE PROTEIN MODULATORS | Assembly Biosciences, Inc. (US) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018053157-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018053157-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10987360-B2 | Hepatitis B core protein modulators | HAVCR2, FABP1, MAVS | SLC5A2 4627/4885IDO1 2305/4885TDO2 3878/4885 |
| US-20190255067-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | SLC5A2 4627/4885IDO1 2305/4885TDO2 3878/4885 |
| US-20220023311-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | SLC5A2 4627/4885IDO1 2305/4885TDO2 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.